These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

773 related items for PubMed ID: 7519937

  • 1. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M, Hurwitz CA, Krance RA, Coustan-Smith E, Williams LL, Santana V, Ribeiro RC, Brenner MK, Heslop HE.
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [Abstract] [Full Text] [Related]

  • 2. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
    Przepiorka D, Chan KW, Champlin RE, Culbert SJ, Petropoulos D, Ippoliti C, Khouri I, Huh YO, Vreisendorp H, Deisseroth AB.
    Bone Marrow Transplant; 1995 Dec; 16(6):737-41. PubMed ID: 8750262
    [Abstract] [Full Text] [Related]

  • 3. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D, Filipovich A, McGlave P, Ramsay N, Kersey J, Miller W, Blazar B.
    Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
    Sao H, Kitaori K, Kasai M, Shimokawa T, Kato C, Yamanishi H, Ueda R, Morishima Y.
    Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
    [Abstract] [Full Text] [Related]

  • 8. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
    Jabado N, Le Deist F, Cant A, De Graeff-Meeders ER, Fasth A, Morgan G, Vellodi A, Hale G, Bujan W, Thomas C, Cavazzana-Calvo M, Wijdenes J, Fischer A.
    Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation.
    Przepiorka D, LeMaistre CF, Huh YO, Luna M, Saria EA, Brown CT, Champlin RE.
    Ther Immunol; 1994 Apr; 1(2):77-82. PubMed ID: 7584486
    [Abstract] [Full Text] [Related]

  • 10. Prophylaxis for acute graft-versus-host disease following unrelated donor bone marrow transplantation.
    Phillips GL, Nevill TJ, Spinelli JJ, Nantel SH, Klingemann HG, Barnett MJ, Shepherd JD, Chan KW, Meharchand JM, Sutherland HJ.
    Bone Marrow Transplant; 1995 Feb; 15(2):213-9. PubMed ID: 7539667
    [Abstract] [Full Text] [Related]

  • 11. Donor bone marrow treatment with T101 Fab fragment-ricin A-chain immunotoxin prevents graft-versus-host disease.
    Laurent G, Maraninchi D, Gluckman E, Vernant JP, Derocq JM, Gaspard MH, Rio B, Michalet M, Reiffers J, Dreyfus F.
    Bone Marrow Transplant; 1989 Jul; 4(4):367-71. PubMed ID: 2789084
    [Abstract] [Full Text] [Related]

  • 12. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK, deMagalhaes-Silverman M, Hohl RJ, Hayashi M, Buatti J, Wen BC, Schlueter A, Strauss RG, Gingrich RD.
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [Abstract] [Full Text] [Related]

  • 13. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, Rizzo D, Burns WH, Margolis DA, Vesole DH, Horowitz M, Zhang MJ, Juckett M, Drobyski WR.
    Biol Blood Marrow Transplant; 2001 Jan; 7(11):620-30. PubMed ID: 11760150
    [Abstract] [Full Text] [Related]

  • 14. Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors.
    Krance R, Heslop HE, Mahmoud H, Ribeiro R, Douglass E, Hurwitz C, Santana V, Kun L, Horowitz MM, Brenner MK.
    Bone Marrow Transplant; 1993 Jan; 11(1):33-6. PubMed ID: 8431709
    [Abstract] [Full Text] [Related]

  • 15. [T-cell-depleted HLA non-identical bone marrow transplantation in the child: prevention of graft-versus-host reaction by administration of donor T lymphocytes alloreactive against the recipient].
    Cavazzana-Calvo M, André-Schmutz I, Hacein-Bey S, Schindler J, Vitetta H, Dupuis S, Quartier P, Chedeville G, Vilmer E, Casanova JL, Buffet R, Caillat-Zucman S, Radford I, Le Deist F, Fischer A.
    J Soc Biol; 2001 Jan; 195(1):65-8. PubMed ID: 11530503
    [Abstract] [Full Text] [Related]

  • 16. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors.
    Ash RC, Casper JT, Chitambar CR, Hansen R, Bunin N, Truitt RL, Lawton C, Murray K, Hunter J, Baxter-Lowe LA.
    N Engl J Med; 1990 Feb 22; 322(8):485-94. PubMed ID: 2300120
    [Abstract] [Full Text] [Related]

  • 17. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
    Ji SQ, Chen HR, Wang HX, Yan HM, Liu J, Xue M, Zhu L.
    Zhonghua Xue Ye Xue Za Zhi; 2003 Aug 22; 24(8):416-9. PubMed ID: 14642179
    [Abstract] [Full Text] [Related]

  • 18. A new approach to the prevention of graft-versus-host disease using XomaZyme-H65 following histo-incompatible partially T-depleted marrow grafts.
    Henslee PJ, Byers VS, Jennings CD, Marciniak E, Thompson JS, Macdonald JS, Romond EH, Messino MJ, Scannon PJ.
    Transplant Proc; 1989 Feb 22; 21(1 Pt 3):3004-7. PubMed ID: 2650413
    [No Abstract] [Full Text] [Related]

  • 19. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
    Hale G, Waldmann H.
    Bone Marrow Transplant; 1994 May 22; 13(5):597-611. PubMed ID: 8054913
    [Abstract] [Full Text] [Related]

  • 20. Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb.
    Patel NC, Chinen J, Rosenblatt HM, Hanson IC, Brown BS, Paul ME, Abramson SL, Ritz J, Shearer WT.
    J Allergy Clin Immunol; 2008 Dec 22; 122(6):1185-93. PubMed ID: 19084111
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.